| |
| |
|
| Insider
Information: |
Bentsur Ron |
| Relationship: |
Chairman & CEO, Direct... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
4,188,470 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$52,464 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
4,188,470 |
|
|
| Total
Value |
$52,464 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Keryx Biopharmaceuticals Inc |
KERX |
Chief Executive Office... |
2015-04-06 |
777,209 |
|
0 |
Premium* |
|
|
XTL Biopharmaceuticals Ltd |
XTLBY |
CEO |
2007-08-21 |
20,101 |
|
0 |
Premium* |
|
|
Stemline Therapeutics Inc |
STML |
Director |
2020-06-10 |
0 |
|
0 |
Premium* |
|
|
Beyond Air Ord Shs |
XAIR |
Director |
2023-03-20 |
144,736 |
|
0 |
Premium* |
|
|
Nuvectis Pharma, Inc. |
NVCT |
Chairman & CEO, Direct... |
2024-05-14 |
3,246,424 |
2022-02-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
152 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-10-09 |
4 |
B |
$11.19 |
$9,288 |
D/D |
830 |
3,236,844 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-16 |
4 |
B |
$19.32 |
$19,320 |
D/D |
1,000 |
2,959,404 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-20 |
4 |
B |
$16.28 |
$16,280 |
D/D |
1,000 |
2,962,614 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-08-29 |
4 |
B |
$9.07 |
$9,070 |
D/D |
1,000 |
3,008,909 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-09-23 |
4 |
B |
$7.93 |
$7,930 |
D/D |
1,000 |
3,011,609 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-11-10 |
4 |
B |
$7.07 |
$7,070 |
D/D |
1,000 |
3,014,109 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-09-02 |
4 |
B |
$8.37 |
$10,044 |
D/D |
1,200 |
3,010,609 |
3.15 |
- |
|
| STML |
Stemline Therapeutics Inc |
Director |
– • – |
2015-03-18 |
4 |
S |
$16.12 |
$22,375 |
D/D |
(1,388) |
7,285 |
0 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-10-05 |
4 |
B |
$11.09 |
$15,526 |
D/D |
1,400 |
3,235,764 |
3.15 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2021-02-11 |
4 |
S |
$6.28 |
$9,420 |
D/D |
(1,500) |
182,436 |
0 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2020-08-25 |
4 |
AS |
$5.95 |
$9,406 |
D/D |
(1,580) |
189,636 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2015-04-06 |
4 |
S |
$11.68 |
$18,595 |
D/D |
(1,592) |
777,209 |
0 |
- |
|
| XTLBY |
XTL Biopharmaceuticals Lt... |
CEO |
• – – |
2006-08-25 |
4 |
B |
$2.98 |
$4,768 |
D/D |
1,600 |
4,822 |
2.66 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-03-14 |
4 |
B |
$10.85 |
$18,228 |
D/D |
1,680 |
3,227,139 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-18 |
4 |
B |
$18.49 |
$32,910 |
D/D |
1,700 |
2,961,414 |
3.23 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2014-07-07 |
4 |
S |
$15.75 |
$28,161 |
D/D |
(1,788) |
876,815 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2013-04-05 |
4 |
S |
$6.93 |
$12,439 |
D/D |
(1,795) |
464,010 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2014-04-03 |
4 |
S |
$16.46 |
$29,891 |
D/D |
(1,816) |
878,603 |
0 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-10-04 |
4 |
B |
$10.95 |
$19,929 |
D/D |
1,820 |
3,234,364 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2024-05-14 |
4 |
B |
$6.74 |
$13,076 |
D/D |
1,940 |
3,246,424 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2024-05-10 |
4 |
B |
$6.40 |
$12,800 |
D/D |
2,000 |
3,244,484 |
3.15 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2014-10-03 |
4 |
S |
$16.14 |
$32,893 |
D/D |
(2,038) |
824,777 |
0 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2023-03-20 |
4 |
B |
$6.48 |
$14,904 |
D/D |
2,300 |
144,736 |
2.39 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2013-07-05 |
4 |
S |
$7.95 |
$19,398 |
D/D |
(2,440) |
461,570 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2013-10-03 |
4 |
S |
$10.25 |
$25,676 |
D/D |
(2,505) |
459,065 |
0 |
- |
|
152 Records found
|
|
Page 3 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
